Fig. 4From: A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomasCorrelation between mTOR inhibition and response to therapy. Cells obtained from a core biopsy at week 4 were stained for either pS6K (a) or pAKT (b), and compared with staining from the diagnostic biopsy. Inhibition of phosphorylation was compared with response or nonresponse to treatmentBack to article page